Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
How to choose the right real-time RT-PCR primer sets for the SARS-CoV-2 genome detection?

Ahalieyah Anantharajah a,b,*, Raphaël Helaers c, Jean-Philippe Defour d,e, Nathalie Olive b, Florence Kabera b, Luc Croonen b, François Deldime b, Jean-Luc Vaerman b, Cindy Barbée b, Monique Bodés a, Anais Scohy a, Alexia Verroken a, Hector Rodriguez-Villalobos a, Benoît Kabamba-Mukadi a,b

a Department of Microbiology, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium
b Department of Molecular Biology, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium
c Human Molecular Genetics, de Duve Institute, Université catholique de Louvain, Brussels, Belgium
d Department of Hematology, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium
e Ludwig Institute for Cancer Research & de Duve Institute, Université catholique de Louvain, Brussels, Belgium

ARTICLE INFO

Keywords:
SARS-CoV-2
Real-time RT PCR
Molecular detection
In silico analysis
Clinical performance
COVID-19

ABSTRACT

Objectives: The SARS-CoV-2 pandemic has created an unprecedented need for rapid large-scale diagnostic testing to prompt clinical and public health interventions. Currently, several quantitative reverse-transcription polymerase chain reaction (RT-qPCR) assays recommended by the World Health Organization are being used by clinical and public health laboratories and typically target regions of the RNA-dependent RNA polymerase (RdRp), envelope (E) and nucleocapsid (N) coding region. However, it is currently unclear if results from different tests are comparable. This study aimed to clarify the clinical performances of the primer/probe sets designed by US CDC and Charité/Berlin to help clinical laboratories in assay selection for SARS-CoV-2 routine detection.

Methods: We compared the clinical performances of the recommended primer/probe sets using one hundred nasopharyngeal swab specimens from patients who were clinically diagnosed with COVID-19. An additional 30 “pre-intervention screening” samples from patients who were not suspected of COVID-19 were also included in this study. We also performed sequence alignment between 31064 European SARS-CoV-2 and variants of concern genomes and the recommended primer/probe sets.

Results: The present study demonstrates substantial differences in SARS-CoV-2 RNA detection sensitivity among the primer/probe sets recommended by the World Health Organization especially for low-level viral loads. The alignment of thousands of SARS-CoV-2 sequences reveals that the genetic diversity remains relatively low at the primer/probe binding sites. However, multiple nucleotide mismatches might contribute to false negatives.

Conclusion: An understanding of the limitations depending on the targeted genes and primer/probe sets may influence the selection of molecular detection assays by clinical laboratories.

1. Introduction

Efforts to control SARS-CoV-2, the novel coronavirus causing COVID-19 pandemic, depend on accurate and rapid diagnostic testing. The reverse transcription real-time polymerase chain reaction (RT-qPCR) assay has become the gold standard for the diagnosis of SARS-CoV-2 infection. The European Commission advised to follow one of the World Health Organization protocols of RT-qPCR assays, published as early as January 2020 (WHO, 2020; European Commission, 2020). Among them, the United States Center for Disease Control (US CDC) recommended two nucleocapsid gene targets (N1 and N2) (Holshue et al., 2020) while the German Consiliary Laboratory for Coronaviruses hosted at the Charité in Berlin (Charité/Berlin) recommended first line screening with the envelope (E) gene assay followed by a confirmatory...
assay using the RNA-dependent RNA polymerase (RdRp) gene, even before the first COVID-19 cases appeared in Europe (Corman et al., 2020; Reusken et al., 2020). At the time of data submission 437 molecular assays are commercially available or in development for the diagnosis of COVID-19 (https://www.finddx.org/) and most of them use these recommended gene targets alone or in combination. However, there has been no indication that any one of these sequence regions offer an advantage for clinical diagnostic testing, especially as the number of samples from patients with confirmed COVID-19 has been relatively small in the preliminary evaluations. Recent studies reported that the RT-qPCR assays have limited sensitivity, while chest computed tomography (CT) may reveal pulmonary abnormalities consistent with COVID-19, including ground-glass opacities, multifocal patchy consolidation, and/or interstitial changes with a peripheral distribution, even in patients with negative RT-qPCR results (Huang et al., 2020; Ai et al., 2020; Xie et al., 2020). The genomic evolution of SARS-CoV-2 and specifically, the emergence of three new viral variants, at the end of 2020, associated with extensive transmission started to raise concerns (van Dorp et al., 2020; Stefanelli et al., 2020; Wang et al., 2020; González-Candelas et al., 2021). These variants of concern were first reported in the UK (B.1.1.7, South Africa (B.1.351) and Brazil (P.1). Their designation as VOCs was determined by an increase of local cases and by the high number of amino acid substitutions harboured by these lineages, which can lead to increased infectivity and potentially decreased vaccine effectiveness. Genetic variations in the viral genome at primer/probe binding regions could result in potential mismatches and false-negative results. RT-qPCR assays with higher sensitivity targeting conserved regions might help to reduce the false-negative rate.

In the context of lift confinement restrictions where large scale COVID-19 testing should be needed, this study aimed to clarify the clinical performances of the primer/probe sets designed by US CDC and Charité/Berlin to help guide assay selection by clinical laboratories for SARS-CoV-2 routine detection.

2. Material and methods

2.1. In silico analysis of primer and probe sequences

The amplified regions of SARS-CoV-2 by the recommended primers (E_Sarbeco_F1, E_Sarbeco_R2, E_Sarbeco_P1; RdRp_SARSr-F2, RdRP_SARSr-R1, RdRP_SARSr-P2; 2019-nCov_N1-F, 2019-nCov_N1-R, 2019-nCov_N1-P; 2019-nCov_N2-F, 2019-nCov_N2-R, 2019-nCov_N2-P) were aligned with SARS-CoV, SARS-CoV-2 and seasonal human coronaviruses genome using MUSCLE (Madeira et al., 2019), and formatted using MSAViewer (Yachdav et al., 2016). Phylogenies have been inferred using MetaPIGA 3.1 (Helaers and Milinkovitch, 2010) with “Human CoV 229E” selected as an outgroup. Resulting consensus trees have been formatted using iTOL.

In addition, 31064 SARS-CoV-2 sequences from 32 European countries and 4078 well-characterized SARS-CoV-2 sequences from 173 countries in the World have been downloaded from Global Initiative on Sharing All Influenza Data (GISAID) (Shu and McCauley, 2017), and aligned against N1, N2, RdRp and E primers/probe sequences using the Smith–Waterman algorithm (Smith and Waterman, 1981).

2.2. Clinical specimens

From April 1 to April 30, 2020, we retrospectively collected one hundred nasopharyngeal swab specimens from patients who were clinically diagnosed with COVID-19 according to the chest CT image and hospitalized in COVID-19 care units of the Cliniques universitaires Saint-Luc, in Brussels, Belgium. An additional 30 “pre-intervention screening” samples from patients who were not suspected of COVID-19 were also included in this study. The nasopharyngeal swabs were eluted in 1 mL of universal viral transport media (UTM, Copan, Italia). Nucleic acids were extracted from 650 μL of nasopharyngeal swab medium by the Abbott m2000sp following manufacturer’s magnetic microparticle-based protocol (Abbott molecular, IL, USA). Samples were eluted in 60 μL of elution buffer.

2.3. Real-time RT-PCR assays

The reaction mix (20 μL) consisted of 4x TaqPath™1 1-Step RT-qPCR Master Mix, CG (ThermoFisher, Waltham, MA, USA), 5 μL of extracted nucleic acid and primers/probes at concentrations recommended by Charité/Berlin and CDC protocols (Integrated DNA Technologies, Corvallis, IA, USA) (WHO, 2020). A multiplexing assay with 2019-nCoV_N1 and 2019-nCoV_N2 was also evaluated in parallel. We used human RNase P as control for RNA extraction, and as indicator of the sample quality. The RT-qPCR was performed on LightCycler 480 II (Roche Diagnostics, Mannheim, Germany) with the following amplification parameters: 10 min at 55 °C for reverse transcription, 3 min at 95 °C for activation followed by 45 cycles of 15 s at 95 °C and 30 s at 58 °C (Corman et al., 2020). We also tested samples for SARS-CoV-2 using the RdRp genesig® Real-Time PCR COVID-19 CE IVD assay (Primedesign Ltd, Chandler’s Ford, UK) according to the manufacturer’s instructions. RT-qPCR efficiency, linearity and viral load were determined using a 10-fold dilution standard curve of SARS-CoV-2 RNA transcripts standard (Bio-Rad, Hercules, CA, USA) with three replicates at each concentration. Statistical analysis was performed using GraphPad Prism software (San Diego, USA).

3. Results

3.1. Oligonucleotide binding regions alignments

No significant homologies of SARS-CoV-2 sequences with MERS-CoV and seasonal human coronaviruses HKU1, OC43, NL63, 229E were observed suggesting a low risk of potential false positive RT-qPCR results with other circulating human coronaviruses. However, due to the relative paucity of positive control materials at the time these assays were developed, the primers and probe were designed such that they would also cross-react with the SARS-CoV (Corman et al., 2020; Chu et al., 2020). Indeed, probe and primers sequences of E gene assay showed high sequence homology with other related betacoronaviruses such as SARS coronavirus and bat SARS-like coronavirus genomes (Corman et al., 2020). Although the forward and reverse primer sequences of RdRp and N2 assays showed high sequence homology with SARS coronavirus, the combination of primers and probe would allow the specific detection of SARS-CoV-2. The assay targeting N1 gene was found to be specific to SARS-CoV-2 (Fig. 1).

To assess if these recommended primers and probes covered the circulating strains in Europe, 31064 SARS-CoV-2 sequences were downloaded from GISAID (Shu and McCauley, 2017), and compared to the primers and probe binding regions (Smith and Waterman, 1981) (Table 1A). A single nucleotide mismatch was found in RdRP_SARSr-R2 reverse primer binding region with 99.9 % of SARS-CoV-2 analyzed genomes. The primer (CARATGTAAASACACTATGGCATA) contained an incorrect degenerate base S at position 12 that binds with G or C while all SARS-CoV-2 analyzed sequences encoded for a T at this position. This mismatch would not be derived from a new variant but rather due to the initial oligonucleotide design allowing to amplify SARS-CoV, bat-SARS-related CoV and SARS-CoV-2 genomes. Over 98 % of analyzed sequences of SARS-CoV-2 showed exact identity to N1, N2 and E primers and probe sequences. The remaining sequences of SARS-CoV-2 exhibited mainly single base-pair mismatches. N1 and N2 binding regions appeared to carry more mutations than E and RdRp binding regions. At least one mutation in last five nucleotides of 3’ primer regions (forward, probe or reverse) were observed in 615 (2 %) deposited sequences which could affect sensitivity. The alignment of the variants of concern B.1.1.7, B.1.351, P.1 sequences (Table 1B) and the variants of interest B.1.525, B.1.427/B.1.429, P.2 and P3 sequences against the sets of primer/probe alignments...
3. Clinical performances

The RT-qPCR efficiencies of the recommended primer/probe sets, calculated using 10-fold serial dilution of RNA transcripts standard were above 90 % which match the criteria for an efficient RT-qPCR assay (Svec et al., 2015). The limit of detection was 5 copies per reaction for the N1 and N2 gene assays, 10 copies per reaction for the E gene assay and 25 copies per reaction for the RdRp-P2 assay (Table 2).

We collected nasopharyngeal samples from one hundred patients who presented Chest CT abnormalities consistent with COVID-19 (median age, 63.5 years; 51 % female). The average length of stay in COVID-19 care units was 12 days with 15 deaths as of April 30th 2020. The nasopharyngeal specimens were obtained upon hospital admission corresponding to an average of 5.6 days (range: 1–16) after symptoms onset.

Mean Ct values of the sample cohort detected by all RT-qPCR assays were significantly lower in N1 and N2 gene assays than in RdRp-P2 and E gene assay (One way ANOVA, Tukey-post test p < 0.001). Compared to CT-Scan, N1 and N2 primer/probe sets showed the highest positive rate (73 and 74 % respectively) followed by E primer/probe set (58 %) and then RdRp primer/probe sets (44 %) (Table 2). The use of Genesig commercial kit with optimized target region and primer/probe sequences in the RdRp gene exhibited a slightly increased sensitivity (53 %) compared to RdRp-P2 assay recommended by Corman et al. (2020).

Interestingly, the combination of N1 and N2 assays allowed an increase in the sensitivity (84 %) compared to N1 or N2 alone, including SARS-CoV-2 RNA detection in 5 additional specimens (viral load range: 519–1007 copies/mL) that were tested negative by the others assays (Fig. 2). Among these patients, we could exclude 3 false positive results as patients had positive SARS-CoV-2 IgG (MAGLUMI assay, Snibe) 7–12 days after molecular testing. Serological control could not be performed for the 2 other patients as they died within a short time spanning.

The performances of the RT-qPCR assays were highly dependent on the viral load. In our study, positive SARS-CoV-2 clinical samples exhibited median Ct values >30 corresponding to low viral load which made the detection challenging. Indeed, both RdRp and E assays reliably detected specimens with Ct values <30, but did not detect 40–60 % of specimens with Ct values ≥30 (Table 2, Fig. 2, S1).

4. Discussion

The survey published on February 11, 2020 reported (Reusken et al., 2020) that the E, RdRp- and N- gene assays had rapidly been implemented by the European laboratories. Very few studies have been published to date on the relative performance characteristics of these assays recommended by the WHO (Holshue et al., 2020; Corman et al., 2020; Konrad et al., 2020). One of the key factors determining detection sensitivity is how efficiently primers and probes bind target genes. Our findings highlight substantial differences in sensitivity for the primer/probe sets when comparing under the same conditions. Indeed, N1 and N2 assays stand out in comparison with the RdRp-P2 and E assays for the detection of low-level viral loads. Furthermore, positive E and negative RdRp results were obtained in 15 cases. We may therefore question the need of confirmatory testing following an initial positive test according to the Charité/Berlin protocol, resulting in turnaround time delay and increased workload. The cross-reactivity of the primers and probes with SARS-CoV should not cause any diagnostic ambiguity as SARS-CoV is no longer detected since the resolution of the epidemic in 2004 (Wang et al., 2005). Based on our preliminary observations, multiplexing CDC N1 and N2 assays within a single PCR mixture could allow a reliable SARS-CoV-2 detection. For now, the low variability in the primer/probe binding regions of the SARS-CoV-2 sequences analysed, in particular of the B.1.1.7 VOC sequences can be considered reassuring. However, we observed notable mismatches in regions targeted by the primer/probe sets which might affect RT-qPCR assays performance depending on their location and the nature of the substitution (Klungthong et al., 2010; Stadhouwers et al., 2010).

At present, in the context of large-scale screening, RT-qPCR testing...
Table 1A
Primers alignments with SARS-CoV-2 target sequences.

| Average Position Start sequence | Primer | Primer sequence 5’-3’ | Primer size bp | Identity 100 % Number sequences | 1 nucleotide mismatch Number sequences | Number countries | Number variants | >2 nucleotide mismatches Number sequences | Number countries | Number variants | % sequences with ≥ 2 nucleotide mismatches | Number of sequences with at least one mutation in last 5 nucleotides of 3’ primer region |
|---------------------------------|--------|------------------------|----------------|---------------------------------|------------------------------------------|------------------|---------------|------------------------------------------|------------------|---------------|------------------------------------------|------------------------------------------------|
|                                  |        |                        |                |                                 |                                          |                  |               |                                          |                  |               |                                          |                                                 |
| N1 28267                         |        |                        |                |                                 |                                          |                  |               |                                          |                  |               |                                          |                                                 |
| 2019-nCoV_N1-F                   |        | GACCCCAAATCAGCGAAT     | 20             | 30755                           | 304                                      | 19               | 27            | 5                                        | 5                | 4             | 0,016                     | 37                                                   |
| 2019-nCoV_N1-P                   |        | ACCCGCATTAGTTGGTGACC   | 24             | 30623                           | 437                                      | 22               | 26            | 4                                        | 4                | 3             | 0,013                     | 8                                                    |
| 2019-nCoV_N1-R                   |        | TCTGGTACTGCAGTGAATCTG  | 24             | 30864                           | 196                                      | 16               | 28            | 3                                        | 3                | 2             | 0,010                     | 66                                                   |
| 2019-nCoV_N2-F                   |        | TTACCAATTGCCGCGCAA     | 20             | 30821                           | 162                                      | 18               | 13            | 79                                       | 3                | 4             | 0,254                     | 135                                                  |
| 2019-nCoV_N2-P                   |        |                       |                |                                 |                                          |                  |               |                                          |                  |               |                                          |                                                 |
| 2019-nCoV_N2-R                   |        |                       |                |                                 |                                          |                  |               |                                          |                  |               |                                          |                                                 |
| N2 29144                         |        | ACAATTGCCGCACGGGCTCAG  | 23             | 30798                           | 182                                      | 17               | 16            | 84                                       | 6                | 5             | 0,270                     | 199                                                  |
| 2019-nCoV_N2-P                   |        | GGGCGACATTCGGAAGAA     | 18             | 30858                           | 119                                      | 15               | 10            | 87                                       | 5                | 1             | 0,280                     | 114                                                  |
| E 26249                          |        | ACAGTTAGGTTAATAGTATGGT | 26             | 30978                           | 85                                       | 16               | 13            | 1                                        | 1                | 1             | 0,003                     | 3                                                    |
| E_Sarbeco_F2                     |        | ACACTAGGCAATCTCAGCTG   | 26             | 31002                           | 55                                       | 10               | 9             | 7                                        | 4                | 3             | 0,023                     | 26                                                   |
| E_Sarbeco_P1                     |        | ATATTGACTATATGGGAGCA   | 22             | 31039                           | 17                                       | 8                | 8             | 8                                        | 5                | 3             | 0,026                     | 15                                                   |
| E_Sarbeco_R1                     |        | GTGARATGTCATGACGGG     | 22             | 31093                           | 160                                      | 15               | 12            | 1                                        | 1                | 1             | 0,003                     | 93                                                   |
| RdRp_SARSr-F1                    |        |                       |                |                                 |                                          |                  |               |                                          |                  |               |                                          |                                                 |
| RdRp_SARSr-P1                    |        |                       |                |                                 |                                          |                  |               |                                          |                  |               |                                          |                                                 |
| RdRp_SARSr-R2                    |        |                       |                |                                 |                                          |                  |               |                                          |                  |               |                                          |                                                 |
| RdRp_SARSr-P2                    |        |                       |                |                                 |                                          |                  |               |                                          |                  |               |                                          |                                                 |
| RdRp_SARSr-R2                    |        |                       |                |                                 |                                          |                  |               |                                          |                  |               |                                          |                                                 |

31064 SARS-CoV-2 sequences from 32 European countries (Austria, Belgium, Belarus, Bosnia and Herzegovina, Croatia, Czech Republic, England, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Lithuania, Netherlands, North Macedonia, Northern Ireland, Norway, Poland, Romania, Russia, Scotland, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, Wales) have been downloaded from GISAID (as available from 19th to 24th April 2021), and aligned against the sets of primer/probe. R is G/A and S is G/C. *Only complete human SARS-CoV-2 genomes were included in the analysis.
| Primer  | N1                | N2                | E                | RdRp               |
|---------|-------------------|-------------------|------------------|--------------------|
|         | All sequences (n=4078) | B.1.1.7 [GRY/20I/501Y.V1] (n=1169) | B.1.351 [GH/20I/501Y.V2] (n=163) | P.1 [GR/20J/501Y.V3] (n=46) |
|         | Number sequences with 100 % identity | Number sequences with 1 mismatch | Number sequences with ≥ 2 mismatches | Number sequences with 100 % identity | Number sequences with 1 mismatch | Number sequences with ≥ 2 mismatches | Number sequences with 100 % identity | Number sequences with 1 mismatch | Number sequences with ≥ 2 mismatches |
| 2019-nCoV_N1-F | 4009 | 60 | 9 | 1158 | 8 | 3 | 157 | 6 | 0 | 44 | 2 | 0 |
| 2019-nCoV_N1-P | 3949 | 121 | 8 | 1167 | 3 | 2 | 144 | 19 | 0 | 44 | 2 | 0 |
| 2019-nCoV_N1-R | 4042 | 26 | 9 | 1165 | 2 | 2 | 161 | 2 | 0 | 46 | 0 | 0 |
| 2019-nCoV_N2-F | 4010 | 34 | 34 | 1159 | 1 | 9 | 159 | 0 | 4 | 46 | 0 | 0 |
| 2019-nCoV_N2-P | 3994 | 50 | 33 | 1140 | 20 | 9 | 159 | 0 | 4 | 46 | 0 | 0 |
| 2019-nCoV_N2-R | 4023 | 18 | 37 | 1159 | 0 | 10 | 159 | 0 | 4 | 46 | 0 | 0 |
| E_Sarbeco_F2 | 4062 | 7 | 9 | 1166 | 3 | 0 | 162 | 0 | 1 | 46 | 0 | 0 |
| E_Sarbeco_P1 | 4062 | 4 | 12 | 1167 | 0 | 2 | 162 | 0 | 1 | 46 | 0 | 0 |
| E_Sarbeco_R1 | 4056 | 4 | 18 | 1164 | 1 | 4 | 162 | 0 | 1 | 46 | 0 | 0 |
| RdRP_SARSr_F1 | 4039 | 36 | 3 | 1163 | 4 | 2 | 161 | 2 | 0 | 46 | 0 | 0 |
| RdRP_SARSr_P2 | 4060 | 12 | 6 | 1167 | 0 | 2 | 163 | 0 | 0 | 46 | 0 | 0 |
| RdRP_SARSr_R2 | 1 | 4073 | 4 | 1 | 1168 | 0 | 0 | 163 | 0 | 0 | 46 | 0 | 0 |

4078 well-characterized SARS-CoV-2 sequences from 173 countries in the World have been downloaded from GISAID (Global Region-specific Auspice source files) and aligned against the sets of primer/probe. 356 different lineages (Pangolin nomenclature) and 12 or 9 different clades (Nextstrain and GISAID nomenclature respectively) were represented including the variants of concern (VOCs) in Europe (B.1.1.7 first detection in United Kingdom; B.1.351 first detection in South Africa; P.1 first detection in Brazil).
remains the standard for the diagnosis of COVID-19 despite the false-negative rate. Indeed, normal chest CT scan cannot exclude COVID-19, especially for patients with early symptoms (Yang and Yan, 2020) and conversely an abnormal CT scan is not specific for COVID-19 diagnosis (Hope et al., 2020). We believe our results would encourage the laboratory staff to be aware of certain limitations depending on the targeted genes and to evaluate the clinical performances of COVID-19 molecular diagnostic tests across a wide range of viral concentrations before their implementation. Due to the extensive transmission of this virus, the genetic diversity in the SARS-CoV-2 genome and the constant emergence of variants of concern, we also encourage the detection of SARS-CoV-2 by targeting at least two distinct regions and oligonucleotide binding regions should be monitored continuously with the circulating virus strains.

CRediT authorship contribution statement

Ahalieyah Anantharajah: Conceptualization, Methodology, Investigation, Formal analysis, Writing - original draft. Raphael Helaers: Conceptualization, Methodology, Software, Formal analysis, Writing - review & editing. Jean-Philippe Defour: Conceptualization. Nathalie Olive: Investigation. Florence Kabera: Investigation. Luc Croonen: Investigation. Françoise Deldime: Conceptualization, Investigation, Writing - review & editing. Jean-Luc Vaerman: Conceptualization, Writing - review & editing. Cindy Barbee: Conceptualization, Resources. Monique Bodeus: Writing - review & editing. Anais Scohy:

Fig. 2. Comparison of the viral load detected by the six RT-qPCR assays among the positive nasopharyngeal swabs (n = 84).

The viral load is expressed in log copies/mL and each clinical sample is represented by a circle. The white circles represent clinical samples detected by all RT-qPCR assays while colored circles represent samples not detected by the six assays. Bars represent the median and 95 % Confidence Interval.

Table 2
Comparison of the six RT-qPCR assays performances.

| RT-qPCR assays | PCR efficiency (%/linearity (R²)) | Limit of detection (copies/reaction) | Pre-intervention screening (n = 30) | Chest CT-Scan positive |
|----------------|----------------------------------|-----------------------------------|-----------------------------------|------------------------|
|                | | Negative agreement % (95 % CI) | Positive agreement % (95 % CI) | Median Ct (95 % CI) | Median Viral Load Log copies/mL (95 % CI) | Ct value <30 (n = 19) | Ct value ≥30 (n = 65) | Positive rate % (95 % CI) | Positive rate % (95 % CI) |
| N1             | 96.81/ 0.99                     | 5                                 | 73 (63.6–80.7)                  | 29.59 (29.8–31.8) | 5.07 (4.42–5.89) | 83.1 (72.2–90.3) |
| N2             | 91.62/ 1.00                     | 5                                 | 74 (64.6–81.6)                  | 30.5 (27.92–32.83) | 5.06 (4.40–5.79) | 84.6 (73.9–91.4) |
| N1 + N2        | 92.85/ 1.00                     | 5                                 | 84 (75.8–89.9)                  | 29.35 (26.82–31.64) | 5.11 (4.46–5.83) | 100 (94.4–100) |
| RdRp           | 96.90/ 1.00                     | 25                                | 100 (88.6–100)                 | 31.44 (34.7–53.8) | 5.46 (4.92–5.95) | 38.5 (27.6–50.6) |
| RdRp Genesig®  | 80.27/ 0.99                     | 10                                | 53 (43.3–62.5)                 | 31.67 (28.87–33.41) | 4.47 (4.02–5.18) | 52.3 (40.4–64.0) |
| E              | 95.68/ 1.00                     | 10                                | 58 (48.2–67.2)                 | 31.06 (28.25–33.76) | 4.98 (4.19–5.79) | 60.0 (47.8–71.0) |

N1: y = −3.4007x + 36.624; N2: y = −3.5407x + 37.783; N1 + N2: y = −3.506x + 36.74; RdRp: y = −3.4007x + 37.783; RdRp Genesig®: y = −3.5407x + 37.783; E: y = −3.4007x + 37.84.

PCR efficiency, linearity and virus copies were determined using a 10-fold dilution standard curve of RNA transcripts.

PCR Efficiency E = 100 * (10^−1/slope − 1).

The Limit of detection was determined as the lowest concentration where 100 % (10/10) of the replicates were positive.
Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

The extraordinary availability of genomic data during the COVID-19 pandemic has been made possible thanks to a tremendous effort by hundreds of researchers depositing SARS-CoV-2 assemblies. We acknowledge the authors, originating and submitting laboratories of the sequences from GISAID’s EpiFlu Database on which this research is based. We also thank for excellent technical assistance the members of the molecular biology laboratory of the cliniques universitaires Saint-Luc and Dr A. Nedelec and Pr S. N. Constantinescu (Institut De Duve, Université catholique de Louvain, Brussels), for the kind gift of the control plasmids for \(N\) and \(RdRp\) genes.

Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:https://doi.org/10.1016/j.jviromet.2021.114197.

References

Ai, T., Yang, Z., Hou, H., et al., 2020. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology (February), 200642.

Chu, D.K.W., Pan, Y., Cheng, S.M.S., et al., 2020. Molecular diagnosis of a novel coronavirus (2019-nCoV) causing an outbreak of pneumonia. Clin. Chem. 66 (April (4)), 549–555.

Corman, V.M., Landt, O., Kaiser, M., et al., 2020. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 25 (January (3)).

European Commission. Current performance of COVID-19 test methods and devices and proposed performance criteria 2020 [updated 21 April, 2020;16 April, 2020]. Available from: https://ec.europa.eu/dgs/health/en/disease-prevention/coronavirus/docs/40805.

Gonzalez-Candelas, F., Shaw, M.A., Phan, T., et al., 2021. One year into the pandemic: short-term evolution of SARS-CoV-2 and emergence of new lineages. Infect. Genet. Evol. (April (92)), 104869

Helaers, R., Milinkovitch, M.C., 2010. MetaPIGA v2.0: maximum likelihood large phylogeny estimation using the metatoolkit population genetic algorithm and other stochastic heuristics. BMC Bioinf. (July (11)), 379.

Holshue, M.L., DeRolt, C., Lindquist, S., et al., 2020. First case of 2019 novel coronavirus in the United States. N. Engl. J. Med. 382 (March (10)), 929–936.

Hope, M.D., Raptis, C.A., Henry, T.S., 2020. Chest computed tomography for detection of coronavirus disease 2019 (COVID-19): don’t rush the science. Ann. Intern. Med. (April).

Huang, F., Liu, T., Huang, L., et al., 2020. Use of chest CT in combination with negative RT-PCR assay for the 2019 novel coronavirus but high clinical suspicion. Radiology 295 (April (1)), 22–25.

Klungthong, C., Chinsawatthipisan, P., Hussem, K., et al., 2010. The impact of primer and probe-template mismatches on the sensitivity of pandemic influenza A/H1N1/2009 virus detection by real-time RT-PCR. J. Clin. Virol. 48 (June (2)), 91–95.

Konrad, R., Eberle, U., Dangel, A., et al., 2020. Rapid establishment of laboratory diagnostics for the novel coronavirus SARS-CoV-2 in Bavaria, Germany, February 2020. Euro Surveill. 25 (March (9)).

Madeira, F., Park, Y.M., Lee, J., et al., 2019. The EMBL-EBI search and sequence analysis tools APIs in 2019. Nucleic Acids Res. 47 (July (W1)), W636–W641.

Reusken, C., Broberg, E.K., Haagmans, B., et al., 2020. Laboratory readiness and response for novel coronavirus (2019-nCoV) in expert laboratories in 30 EU/EEA countries, January 2020. Euro Surveill. 25 (February (6)).

Shu, Y., McCauley, J., 2017. GISAID: global initiative on sharing all influenza data - from vision to reality. Euro Surveill. 22 (March (13)).

Smith, T.F., Waterman, M.S., 1981. Identification of common molecular subsequences. J. Mol. Biol. 147 (March (1)), 195–197.

Stadhouders, R., Pas, S.D., Anber, J., et al., 2010. The effect of primer-template mismatches on the detection and quantification of nucleic acids using the 5’ nuclease assay. J. Mol. Diagn. 12 (January (1)), 109–117.

Stefanelli, P., Faggioni, G., Lo Presti, A., et al., 2020. Whole genome and phylogenetic analysis of two SARS-CoV-2 strains isolated in Italy in January and February 2020: additional clues on multiple introductions and further circulation in Europe. Euro Surveill. 25 (April (13)).

Svec, D., Tichopad, A., Novosadova, V., et al., 2015. How good is a PCR efficiency estimate: recommendations for precise and robust qPCR efficiency assessments. Biomol. Detect. Quantif. 3 (March), 9–16.

van Dorp, L., Acman, M., Richard, D., et al., 2020. Emergence of genomic diversity and recurrent mutations in SARS-CoV-2. Infect. Genet. Evol. (May), 104351.

Wang, M., Yan, X., Xu, H., et al., 2005. SARS-CoV infection in a restaurant from palm civet. Emerg. Infect. Dis. 11 (December (12)), 1860–1865.

Wang, M., Li, M., Ren, R., et al., 2020. International expansion of a novel SARS-CoV-2 mutant. J. Virol. (April).

WHO. 2020. COVID-19 Technical Guidance: In House Molecular Assays. Available from: https://www.who.int/docs/default-source/coronaviruse/whoinhouseassays.pdf? sfvrsn=de3a76aa_2

Xie, X., Zhong, Z., Zhao, W., et al., 2020. Chest CT in combination with negative RT-PCR testing. Radiology (February), 200343.

Yachdav, G., Wilzbach, S., Rauscher, B., et al., 2016. MSAViewer: interactive JavaScript visualization of multiple sequence alignments. Bioinformatics 32 (November (22)), 3501–3503.

Yang, W., Yan, F., 2020. Coronavirus disease 2019 (COVID-19): don’t rush the science. Ann. Intern. Med. (April).